> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tremfya 80% Response Rate in Ulcerative Colitis: Janssen
- URL: https://www.fdaweb.com/tremfya-80-response-rate-in-ulcerative-colitis-janssen/
- Published: 2022-10-25T12:00:00.000Z
- Updated: 2026-09-14T18:04:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153048

Janssen Pharmaceutical says new data show that patients given Tremfya (guselkumab) saw a clinical response rate of about 80% in trial subjects with moderately to severely active ulcerative colitis (UC) and who had an inadequate response to previous treatments. The data were from the company’s Phase 2b QUASAR Induction Study 1.

The company says safety findings at week 24 were consistent both with those at week 12 and with the known safety profile for TREMFYA in approved indications. “No new safety concerns for Tremfya were identified,” it says.

The monoclonal antibody is said to selectively bind to the p19 subunit of interleukin (IL)-23 and inhibits its interaction with the IL-23 receptor. It is currently approved for treating certain adults with moderate to severe plaque psoriasis.